Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Defibrillator OTC

This article was originally published in The Gray Sheet

Executive Summary

Philips Medical's HeartStart OnSite will join the HeartStart Home as the first defibrillators available to consumers without a prescription beginning in early February. Additional over-the-counter availability will make defibrillators more accessible to communities, schools and businesses for implementing early defibrillation programs, according to the company. Both devices received FDA clearance in September 2004 (1"The Gray Sheet" Sept. 20, 2004, p. 16)...

You may also be interested in...



Philips Gets FDA Nod For First OTC Defibrillator, Plans TV/Print Ad Campaign

Philips Medical expects its HeartStart Home non-prescription AED to become increasingly affordable for consumers as production volume ramps up

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel